VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Submission of Matters to a Vote of Security Holders

VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 19, 2017, ViewRay, Inc. (the Company) held its Annual
Meeting of Stockholders (the Annual Meeting) at the Companys
offices located at 815 E. Middlefield Road, Mountain View,
California 94043. Only stockholders of record at the close of
business on April 26, 2017, the record date for the Annual
Meeting, were entitled to vote at the Annual Meeting. As of the
record date, 56,455,572 shares of the Companys common stock were
outstanding and entitled to vote at the Annual Meeting. At the
Annual Meeting, 51,831,464 shares of the Companys common stock
were voted in person or by proxy for the two proposals set forth
below, each of which is described in the Companys Definitive
Proxy Statement on Schedule 14A filed with the U.S. Securities
and Exchange Commission on April 28, 2017.

Set forth below, with respect to each such matter, are the number
of votes cast for or against, the number of votes withheld and
the number of broker non-votes.

Proposal No. 1 Election of Directors

The Companys stockholders elected each of James F. Dempsey,
Ph.D., Mark S. Gold, M.D. and Theodore T. Wang, Ph.D. to serve as
Class II directors of the Company until the 2020 Annual Meeting
of Stockholders and until such director’s successor is duly
elected and qualified, or until such director’s earlier death,
resignation or removal.




Broker Non-Votes

James F. Dempsey, Ph.D.




Mark S. Gold, M.D.




Theodore T. Wang, Ph.D.




Proposal No. 2 Ratification of Selection of Independent
Registered Accounting Firm

The Companys stockholders ratified the selection, by the Audit
Committee of the Board of Directors, of Deloitte Touche LLP as
the Companys independent registered public accounting firm for
the Companys fiscal year ending December 31, 2017.




Broker Non-Votes





ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

An ad to help with our costs